Hyderabad/Mumbai Oct 18 : Piramal Pharma Limited (PPL) on Tuesday announced that
Yapan Bio has expanded its capabilities with a new process development facility at Genome
Valley in Hyderabad.
The New facility is part of an $ 8 M USD expansion plan for Yapan bio; represents the first
major expansion since the initial investment from Piramal in December 2021.
The new facility was inaugurated by Telangana Minister for Industries,Mr. K.T. Rama Rao (KTR
) in presence of Piramal Pharma Chairperson Ms. Nandini Piramal, Piramal Enterprises Group
Director ( Strategic Business) Mr. Harinder S. Sikka, Yapan Bio Founders Atin Tomar & Nirav
Desai , Telangana Principal Secretary (IT & Industries) Mr. Jayesh Ranjan and Telangana
Director (Life Sciences) Mr. Shakthi Nagappan.
PPL holds a strategic minority stake in Yapan and markets its services through Piramal Pharma
Solutions (PPS), an industry-leading, patient-centric Contract Development and Manufacturing
Organization (CDMO) serving the global pharmaceutical and biotech market. With this expansion, Yapan has enhanced its ability to support end-to-end development and
manufacturing of RNA, DNA and gene therapy products starting from plasmids.
The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a
downstream process development lab, an analytical development lab, and supporting
infrastructure.
The new labs will allow Yapan to optimize the utilization of the GMP facility to support
manufacturing of clinical trial material for the clients.
Speaking on the occasion Mr. KTR stated, “It is heartening to see that Yapan Bio and Piramal
Pharma have been continuously expanding from Genome Valley. This is testament to the
strength of the biotechnology industry of Telangana. The state of Telangana has been working
with the industry to see how to best match our policies and incentives to their constantly
evolving needs. We will continue to be a partner for growth and ensure that companies like
Yapan Bio continue to grow from the cluster.”
Ms. Nandini Piramal, commented, “This new facility, which is part of our 8 million USD
expansion plan for Yapan Bio, represents the first major step in the Piramal/Yapan partnership
since our initial investment back in December 2021. It’s evidence of our commitment to Yapan
and the large molecule CDMO business, as well as our commitment to patients. With this
investment, the Yapan team can conduct a larger number of projects than before, resulting in the
development and delivery of more novel products for clinical evaluation and ultimately, better,
and faster treatments for patie
Trending Now
E-Paper
Follow our WhatsApp channel